Home
Conditions
Recurrent Mantle Cell Lymphoma

Clinical trial condition

Recurrent Mantle Cell Lymphoma

Explore clinical trials studying Recurrent Mantle Cell Lymphoma. Study availability and eligibility vary by location and protocol.

147 public trials 9 recruiting studies

Refine in advanced search Browse all conditions

Recurrent Mantle Cell Lymphoma trial results

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations: University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada

View Trial Details

Active, not recruiting

Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

NCT03479268

Conditions: B-Cell Prolymphocytic Leukemia, Chronic Disease, Disease Attributes, +40 more
Locations: City of Hope Medical Center Duarte, California, United States

Roswell Park Comprehensive Cancer Center Buffalo, New York, United States

View Trial Details

Active, not recruiting

Copanlisib and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

NCT04939272

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma

NCT02051257

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

NCT01199562

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, +245 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Active, not recruiting

Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

NCT02153580

Conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, Burkitt Lymphoma, +43 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

View Trial Details

Active, not recruiting

Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma

NCT03147885

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Diffuse Large B-cell Lymphoma, +35 more
Locations: Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States

View Trial Details

Completed

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

NCT03015896

Conditions: Blood Protein Disorders, Burkitt Lymphoma, Cardiovascular Diseases, +42 more
Locations: Emory University Atlanta, Georgia, United States

Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States

View Trial Details

Completed

Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma

NCT03440567

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +14 more
Locations: City of Hope Medical Center Duarte, California, United States

View Trial Details

Completed

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

NCT04205409

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +46 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recurrent Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma trial results

Related conditions